| pubmed-article:19625344 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19625344 | lifeskim:mentions | umls-concept:C0010828 | lld:lifeskim |
| pubmed-article:19625344 | lifeskim:mentions | umls-concept:C0059985 | lld:lifeskim |
| pubmed-article:19625344 | lifeskim:mentions | umls-concept:C0376249 | lld:lifeskim |
| pubmed-article:19625344 | lifeskim:mentions | umls-concept:C1521750 | lld:lifeskim |
| pubmed-article:19625344 | lifeskim:mentions | umls-concept:C0439590 | lld:lifeskim |
| pubmed-article:19625344 | lifeskim:mentions | umls-concept:C2926735 | lld:lifeskim |
| pubmed-article:19625344 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:19625344 | pubmed:dateCreated | 2010-1-29 | lld:pubmed |
| pubmed-article:19625344 | pubmed:abstractText | Fludarabine-based chemoimmunotherapy has well-recognised efficacy and short-term toxicity in the treatment of lymphoid malignancies. However, the presence and significance of prolonged cytopenias after completion of treatment have not been thoroughly quantified. | lld:pubmed |
| pubmed-article:19625344 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19625344 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19625344 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19625344 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19625344 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19625344 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19625344 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:19625344 | pubmed:issn | 1569-8041 | lld:pubmed |
| pubmed-article:19625344 | pubmed:author | pubmed-author:WolfMM | lld:pubmed |
| pubmed-article:19625344 | pubmed:author | pubmed-author:RitchieDD | lld:pubmed |
| pubmed-article:19625344 | pubmed:author | pubmed-author:GillSS | lld:pubmed |
| pubmed-article:19625344 | pubmed:author | pubmed-author:JanuszewiczHH | lld:pubmed |
| pubmed-article:19625344 | pubmed:author | pubmed-author:PrinceH MHM | lld:pubmed |
| pubmed-article:19625344 | pubmed:author | pubmed-author:CarneyDD | lld:pubmed |
| pubmed-article:19625344 | pubmed:author | pubmed-author:SeymourJ FJF | lld:pubmed |
| pubmed-article:19625344 | pubmed:author | pubmed-author:WestermanDD | lld:pubmed |
| pubmed-article:19625344 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19625344 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:19625344 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19625344 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19625344 | pubmed:pagination | 331-4 | lld:pubmed |
| pubmed-article:19625344 | pubmed:meshHeading | pubmed-meshheading:19625344... | lld:pubmed |
| pubmed-article:19625344 | pubmed:meshHeading | pubmed-meshheading:19625344... | lld:pubmed |
| pubmed-article:19625344 | pubmed:meshHeading | pubmed-meshheading:19625344... | lld:pubmed |
| pubmed-article:19625344 | pubmed:meshHeading | pubmed-meshheading:19625344... | lld:pubmed |
| pubmed-article:19625344 | pubmed:meshHeading | pubmed-meshheading:19625344... | lld:pubmed |
| pubmed-article:19625344 | pubmed:meshHeading | pubmed-meshheading:19625344... | lld:pubmed |
| pubmed-article:19625344 | pubmed:meshHeading | pubmed-meshheading:19625344... | lld:pubmed |
| pubmed-article:19625344 | pubmed:meshHeading | pubmed-meshheading:19625344... | lld:pubmed |
| pubmed-article:19625344 | pubmed:meshHeading | pubmed-meshheading:19625344... | lld:pubmed |
| pubmed-article:19625344 | pubmed:meshHeading | pubmed-meshheading:19625344... | lld:pubmed |
| pubmed-article:19625344 | pubmed:meshHeading | pubmed-meshheading:19625344... | lld:pubmed |
| pubmed-article:19625344 | pubmed:meshHeading | pubmed-meshheading:19625344... | lld:pubmed |
| pubmed-article:19625344 | pubmed:meshHeading | pubmed-meshheading:19625344... | lld:pubmed |
| pubmed-article:19625344 | pubmed:meshHeading | pubmed-meshheading:19625344... | lld:pubmed |
| pubmed-article:19625344 | pubmed:meshHeading | pubmed-meshheading:19625344... | lld:pubmed |
| pubmed-article:19625344 | pubmed:meshHeading | pubmed-meshheading:19625344... | lld:pubmed |
| pubmed-article:19625344 | pubmed:meshHeading | pubmed-meshheading:19625344... | lld:pubmed |
| pubmed-article:19625344 | pubmed:meshHeading | pubmed-meshheading:19625344... | lld:pubmed |
| pubmed-article:19625344 | pubmed:meshHeading | pubmed-meshheading:19625344... | lld:pubmed |
| pubmed-article:19625344 | pubmed:meshHeading | pubmed-meshheading:19625344... | lld:pubmed |
| pubmed-article:19625344 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:19625344 | pubmed:articleTitle | The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy. | lld:pubmed |
| pubmed-article:19625344 | pubmed:affiliation | Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Victoria, Australia. | lld:pubmed |
| pubmed-article:19625344 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19625344 | pubmed:publicationType | Evaluation Studies | lld:pubmed |
